Policy Comment Letters
As part of its advocacy mission, the Society for Women's Health Research monitors the activities of the executive branch in the areas of women's health and research. At the request of various federal agencies, SWHR periodically submits public comment letters detailing its positions on issues pertaining to SWHR's public policy priorities.
- SWHR signs onto comment letter to Centers for Medicare & Medicaid Services urging them to reconsider their
approach and instead work with organizations representing patients,
employers and healthcare providers on ways to improve Medicare Advantage
and Medicare Part D that build on the strengths of these programs and in the
best interests of beneficiaries. (February 18, 2014)
- SWHR President and CEO signed onto a letter to Dr. Janet Woodcock, Director of the Center for Drug Evaluation and Research, urging FDA to reconsider its decision regarding a new treatment for HSDD in women. (January 30, 2014)
- SWHR President and CEO sent a letter to Dr. Janet Woodcock,
Director of the Center for Drug Evaluation and Research, urging her to consider
scientific evidence for the effectiveness of new
treatments for HSDD to improve the quality of life for many women.
- SWHR signed on to a comment letter to the FDA regarding public availability of data about how new drugs and devices work in women, minorities, and older Americans. (November 20, 2013)
- SWHR submitted letter to FDA regarding draft guidance proposing to change requirements for demonstrating bioequivalence of generic ophthalmic emulsions, eliminating the need to test these drugs for safety in the human eye. (August 16, 2013)
- SWHR gave oral comments
and submitted written comments to the docket at FDA REMS
Standardization and Evaluation Public Meeting at the White Oak campus. (July
- SWHR submitted comments
and Track and Trace legislation to both House and Senate leadership,
the Senate HELP committee and to the House Energy and Commerce committee,
among others. (July 23, 2013).